Influenza and Influenza Vaccine: A Review

Cynthia Nypaver1, CNM, PhD, WHNP-BC, Cynthia Dehlinger2, CNM, DNP, NP-C, Chelsea Carter3, MSN, NP-C

INTRODUCTION

Influenza, also known as the flu, is a highly contagious respiratory illness caused by a number of RNA influenza viruses that can infect humans. Complications from influenza can cause significant morbidity and mortality.1 Globally, as many as 500,000 people die annually from complications related to influenza. Since 2010, the Centers for Disease Control and Prevention (CDC) estimates seasonal influenza infection has resulted in 9.3 to 45 million cases, 140,000 to 810,000 hospitalizations, and 12,000 to 61,000 deaths annually in the United States.1 For those who contract the infection, the risk of complications and symptom severity can be reduced with antiviral medications if taken as soon as possible, preferably within 24 to 72 hours of onset of symptoms.2

Most influenza infections can be prevented with the annual influenza vaccine.2,3 Primary care clinicians, including midwives and advanced practice registered nurses, are ideally positioned to recommend vaccination for all persons over the age of 6 months, unless contraindicated, and to recognize, diagnose, and manage influenza infection soon after exposure to reduce chances of complications that contribute to this high morbidity and mortality rate. This article provides clinicians with information about influenza identification, management, and prevention. Some of the challenges involved in improving uptake of the influenza vaccine and preventing seasonal influenza epidemics are presented. Influenza in the context of the current severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) pandemic is also discussed.

EPIDEMIOLOGY OF INFLUENZA INFECTION

The seasonal incidence of symptomatic influenza among all residents in the United States is approximately 8%, ranging from 3% to 11% depending on the season.4 In the United States and all countries in the Northern Hemisphere, influenza season typically occurs as early as late October and lasts until May. Some influenza seasons are more virulent than others. The severity of influenza any particular year is dependent upon the propagation and characterizations of the circulating influenza viruses, the availability and uptake of effective vaccines specific to current circulating strains, the host immune response, and the presence of an individual’s comorbidities.5 The CDC classifies the severity of an influenza season by monitoring and calculating 3 key influenza indicators, which are (1) outpatient visits for influenza-like illness, (2) influenza-associated hospitalizations, and (3) influenza/pneumonia-related deaths.5

Race and ethnicity-related disparities in the risk of influenza infection and influenza vaccination uptake exist. The literature suggests that differences in risk of contracting influenza infection may be related to varying levels of exposure (eg, group living conditions like dormitories, correctional facilities, or nursing care facilities), limited or no access to health care, and higher susceptibility to severe infection because of exacerbation of other preexisting health conditions.6

1Nurse-Midwifery and Women’s Health Nurse Practitioner Programs, University of Cincinnati, Cincinnati, Ohio
2Department of Obstetrics and Gynecology, University of Cincinnati, Cincinnati, Ohio
3Family Nurse Practitioner Program, University of Cincinnati, Cincinnati, Ohio

Correspondence
Cynthia Nypaver
Email: cynthia.nypaver@uc.edu

ORCID
Cynthia Nypaver https://orcid.org/0000-0003-1201-3311

© 2021 by the American College of Nurse-Midwives
Quick Points

- Influenza viruses cause significant morbidity and mortality yearly.
- Influenza viruses are constantly changing, making it challenging to predict which strains to include in the yearly, upcoming influenza vaccine.
- It is recommended that all individuals aged at least 6 months receive a yearly influenza vaccine unless contraindicated.
- Interventions that target health care providers, patients, and health care systems improve uptake of the influenza vaccine in people.

American Indians, Alaska Natives, and African Americans are at highest risk of developing serious complications from the flu.6,7 It is believed that this is the result of US health disparities in chronic illnesses that preexist in these populations. Furthermore, non-Hispanic Black adults have a lower rate of vaccination uptake than other adult groups living in the United States, including non-Hispanic whites, Hispanics, and Asian Americans.8,9

Influenza in the Context of the SARS-CoV-2 Pandemic

There is emerging evidence that coinfection of influenza with coronavirus disease 2019 (COVID-19) (the illness caused by SARS-CoV-2) is rare; however, individuals with both infections may be at higher risk of poor health outcomes.10,11 It is plausible that the careful use of social distancing, face covering, and handwashing used for COVID-19 prevention may also mitigate transmission of influenza.

Symptoms experienced by individuals with a respiratory illness are often similar, making it difficult for clinicians to differentiate the diagnosis. Table 1 compares and contrasts symptoms of 4 upper respiratory illnesses, including influenza, COVID-19, the common cold, and seasonal allergies. In addition, an algorithm that may be helpful for clinicians to triage symptoms of influenza or COVID-19 can be found at https://www.cdc.gov/flu/professionals/antivirals/office-evaluation.htm. It is especially critical for health care providers to recommend influenza vaccination because of risks associated with coinfections and to not further burden health care systems that are already strained because of the SARS-CoV-2 pandemic.12

THE INFLUENZA VIRUS

Three types of influenza viruses have been identified that infect humans: types A, B, and C. Type A influenza virus, which can infect humans and animals (eg, bovine, equine, and avian) is the most virulent and is most likely the culprit that can give rise to epidemics and pandemics. Influenza A is subclassified into 2 groups based on 2 virus surface proteins, hemagglutinin (HA) and neuraminidase (NA). There are 18 HAs and 11 NAs, which can combine to yield many varying subtypes or strains (eg, H1N1, H5N1).2,13 Slower to mutate, type B influenza virus does not typically cause as severe disease as does type A and is more commonly seen in children, long-term care facilities, college campuses, and military camps.13 Influenza C virus generally causes mild illness and therefore has not been linked to human influenza epidemics.14

Mutations of the Influenza Virus

Table 2 presents definitions of common terminology used to describe viral behavior with regard to antigenic potential. Genes in the various strains of type A influenza viruses continuously mutate to change the surface proteins, allowing the virus to avoid the host’s immune response. This process, known as antigenic variation, enables the virus to avoid recognition, thus becoming more virulent by evading one’s previously acquired immune response. If the mutation is gradual and minimal, the host (person) may be able to spark an immune response through production of antibodies. This gradual change over time is termed antigenic drift.2 On occasion, a type A influenza virus subtype can cross over to another species and cause illness. An example is avian influenza A viruses, which can cross to humans directly through contaminated environments or through an intermediate host such as a pig. This ability to jump species allows genetic mixing or reassortment to occur and creates a new or novel influenza A virus.15,16 A novel virus may spread quickly and infect many humans because most have little or no immunity protection, creating potential for a pandemic.15,16 The process by which a novel virus is created is termed antigenic shift.2

INFLUENZA INFECTION

It is essential, especially from a public health perspective, that health care clinicians recognize how influenza is transmitted in order to counsel individuals about how to prevent spread of the infection throughout the community. The majority of individuals who seek care for flu-like symptoms have uncomplicated influenza that is self-limiting, and full recovery can be expected.17 However, some individuals can have complications that result in severe disease and death. Clinicians must recognize signs and symptoms of infection and know how to diagnosis it quickly so as to provide timely treatment. The best time to prevent or reduce viral replication with antiviral medications is within 24 hours of symptoms first appearing.2

Transmission and Incubation

Influenza viruses are predominantly spread by large-particle respiratory droplets (particles ≥5 microns) through sneezing, coughing, and speaking. Droplets generally travel 6 feet or less. The virus may also be transmitted by indirect contact such as hand contamination to mucous membranes. If
Table 1. Comparing and Contrasting Symptoms of Influenza, COVID-19, Common Cold, and Seasonal Allergies

| Upper Respiratory Illness Symptoms                  | Influenza | COVID-19 | Common Cold | Seasonal Allergies |
|----------------------------------------------------|-----------|----------|-------------|-------------------|
| Cough                                              | Present   | Present, dry | Present (mild to moderate) | Present (mild) |
| Fever with or without chills                       | Present   | Present   | Rare         | Absent            |
| Fatigue                                            | Present   | Present   | Some         | Absent            |
| General malaise                                    | Present   | Present   | Present      | Absent            |
| Shortness of breath or difficulty breathing         | Present   | Present   | Absent       | Absent            |
| Sore throat                                        | Present   | Uncommon  | Present      | Some              |
| Congestion or runny nose                           | Present   | Present   | Present      | Present           |
| Headache                                           | Present   | Present   | Rare         | Present           |
| Joint pain                                         | Present   | Not reported | Absent      | Absent            |
| Myalgia                                            | Present   | Present   | Absent       | Absent            |
| Ocular symptoms (itchy, red, swollen, eyes)        | Absent    | Absent    | Present      | Present           |
| Rhinorrhea                                         | Absent    | Not reported | Present      | Present           |
| Sneezing                                           | Absent    | Not reported | Present      | Present           |
| Earaches                                           | Absent    | Not reported | Some         | Present           |
| New loss of taste or smell                         | Absent    | Present   | Absent       | Absent            |
| Nausea and/or vomiting                             | Rare      | Some      | Absent       | Absent            |
| Diarrhea                                           | Rare      | Some      | Absent       | Absent            |
| Confusion                                          | Absent    | Some      | Absent       | Absent            |

Sources: Dykewicz et al, Eccles, Jiang et al.

Table 2. Definitions of Common Terminology Used to Describe Viral Behavior

| Terminology                | Definition                                                                                                                                 |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Virulence                  | The capacity of a pathogen, like a virus, to overcome the body's defenses against illness                                                |
| Antigens                   | Molecular structures on the surface of viruses that are capable of triggering an immune response (antibody production)                   |
| Antibody                   | High molecular proteins that are produced after exposure to an antigen (naturally or by vaccination) and act specifically against the antigen through an immune response |
| Antigenic properties       | Describes the antibody or immune response triggered by the antigens on a specific virus                                               |
| Antigenic variation        | The ability of an antigen (e.g., virus) to alter their surface proteins to avoid a host immune response                                   |
| Antigenic characterization  | An analysis of a virus's antigenic properties to assess how related it is to another virus                                               |
| Antigenic drift            | Gradual, small changes (mutations) in the genes of a virus resulting in changes in the surface proteins of the virus                     |
| Antigenic shift            | An abrupt, major change (mutation) in a virus resulting in a new (novel) virus that may lead to a pandemic                              |
| Epidemic                   | An increased, often sudden, spread of a disease above normally expected levels in a geographic population                               |
| Pandemic                   | A large epidemic that has spread over several countries or continents worldwide                                                        |

Source: Centers for Disease Control and Prevention.

A susceptible person touches a contaminated surface such as a phone, countertop, keyboard, door handle, or another individual’s contaminated hand and then places their hand on or near their nose, mouth, or eyes, the virus can be transmitted. Viral transmission has also been implicated via the airborne route (particles ≤5 microns that remain suspended in air) through aerosolization of droplets that can occur with singing, shouting, and specific medical procedures. Influenza viruses can remain infectious on surfaces other than the body for extended periods of time, often days to weeks.

Once an individual is exposed to an influenza virus, it typically takes about 2 days for symptoms of the infection to present, but the incubation period can range from 1 to 4 days. Some people may be contagious 1 to 2 days before they exhibit symptoms and are infectious for 5 to 7 days afterward. The average time people are contagious is 6 days; however, they may be contagious longer if immunocompromised.
**Signs and Symptoms, Complications**

Exhibition of symptoms is usually abrupt; symptoms are listed in Table 1. Typically, people with mild to moderate illness will recover within 2 weeks; however, some individuals will develop severe illness that lasts much longer. The most common complications from influenza infection are pneumonia (either viral or bacterial), bronchitis, sinus infections, ear infections, and worsening of preexisting chronic health problems. People classified as high risk of developing complications from influenza include individuals who are 65 years or older or less than 5 years of age, immunocompromised, pregnant, within 2 weeks of giving birth, or living in group settings (eg, dormitories, military barracks, nursing homes), and individuals who have preexisting chronic illnesses (eg, asthma, congestive heart failure, and diabetes) or obesity.

**Diagnosis**

Diagnosis of influenza is primarily clinical and based on the signs and symptoms. Laboratory confirmation of influenza is possible if needed. The Infectious Diseases Society of America (IDSA) provides guidelines for clinicians including when laboratory confirmation is suggested and which test to order. Laboratory confirmation is suggested in the outpatient setting only if testing will influence clinical management, meaning avoidance of unnecessary antibiotics, additional health care visits, and/or treatment with influenza antiviral medications. During influenza season, laboratory testing is suggested for patients who are at high risk of influenza complications and present to an outpatient setting with one of the following: (1) influenza-like symptoms (with or without fever), (2) pneumonia, (3) nonspecific respiratory illness, or (4) exacerbation of chronic health conditions (eg, asthma or chronic pulmonary obstructive disorder). For patients who are not high risk of influenza complications, testing is considered if they present with flu-like illness, pneumonia, or nonspecific respiratory illness and if use of unnecessary antibiotics, further diagnostic testing, and time in the emergency department may be avoided. Another factor to consider is if chemoprophylaxis with influenza antiviral agents may be needed for individuals living in homes with others who are deemed at high risk of influenza complications. Individuals who are hospitalized during influenza season and have or develop acute respiratory illness (with or without fever) should be tested as well. Prompt treatment should occur especially if influenza is circulating in the home or community. For all individuals reporting upper respiratory symptoms, the health care provider should inquire about a recent positive history of fever, cough, body aches, headaches, sore throat, runny nose, chills, and/or fatigue. A full set of vital signs including a pulse oximetry reading should be obtained. All of these can be done via telehealth using applications on smart phones.

Laboratory testing for influenza should preferably be inexpensive, highly sensitive for detecting influenza virus, and provide results quickly. Having access to rapid testing enables health care providers to initiate antiviral therapy quickly. There are several different types of laboratory tests to detect influenza virus. IDSA provides recommendations for choosing the best test based on assessment in the outpatient or in-hospital setting. In the outpatient setting, rapid molecular assays (eg, nucleic acid amplification tests) are recommended over rapid influenza diagnostic tests (RIDTs) to improve detection rates. Rapid molecular assays, which detect genetic material of the virus, are obtained via a nasopharyngeal (NP) swab. Results are available in 15 to 20 minutes and have a high sensitivity rate of 90% to 95% for detecting influenza.

RIDTs detect influenza virus antigens and are collected via NP swab, nasal aspirates, swabs, or washes. These tests can provide a result in 10 to 15 minutes and are reported as either positive or negative. However, RIDTs have a relatively low sensitivity rate of 50% to 70% and high specificity rate of greater than 90%; thus, they can produce more false negative results than false positive results. Therefore, a negative result does not absolutely rule out influenza infection, and the clinician should consider confirming a negative result with a molecular assay.

In hospitalized patients, reverse-transcription polymerase chain reaction (RT-PCR) or other molecular assays are recommended for diagnosis of influenza. A multiplex RT-PCR assay that targets a panel of respiratory pathogens is used for immunocompromised patients in addition to nonimmunocompromised patients if results may influence care (eg, reduce testing or decrease antibiotic use). Immunofluorescence assays for virus antigen detection or RIDTs should not be used to diagnose influenza in hospitalized patients when more sensitive molecular assays are available. If one of the less sensitive tests is used, follow up with a RT-PCR or other molecular assay to confirm all negative results. Viral cultures should not be used as the initial test to diagnose influenza because they take too long to generate a result and clinical management is delayed. However, viral cultures may be considered to confirm a negative result for RIDTs or immunofluorescence assays. Lastly, serologic testing for the diagnosis of influenza is not recommended because results from a single serum specimen cannot be reliably interpreted.

**MANAGEMENT AND TREATMENT**

Once the diagnosis of influenza is made, the clinician should counsel the individual about personal protective measures to prevent further spread of the illness in the home and community. Examples of effective personal protective measures are respiratory etiquette (covering mouth with elbow or tissue during coughing and sneezing), use of disposable tissues, proper hand hygiene (eg, soap and water and/or alcohol-based gel), and use of facemasks (eg, surgical or N95 respirators). Instructions that alcohol, chlorine, hydrogen peroxide, soaps/detergents, and iodine-based antiseptics kill influenza viruses that are on surfaces should be provided. Social distancing, self-quarantine, and other strategies to reduce airborne transmission of influenza must also be discussed. Improving room ventilation by opening a window and replacing the inside air with clean outdoor air may dilute the sick person's respiratory airborne aerosols to a lower concentration level, decreasing risk of transmission. Air purifiers dilute particles in the air without actually filtering out the virus and therefore are not appropriate for use as a personal protective measure. The patient should also be counseled about the use of acetaminophen or ibuprofen...
for fever and/or body aches. Lastly, the clinician should discuss antiviral medications and alternative or complementary therapies. All persons, including all health care providers, should be encouraged to self-isolate when symptomatic for influenza because isolation is one of the most effective methods of preventing transmission. Arranging coverage for job responsibilities requires cooperation and compassion.

### Antiviral Medications

Antiviral medications can be prescribed for individuals infected with influenza. IDSA recommends that antiviral medication is appropriate in high-risk patients with severe or worsening illness. High-risk groups include those who are aged less than 5 years or 65 years or older, women who are pregnant or postpartum within 2 weeks of birth, people with chronic illnesses, and people who are immunocompromised. Four antiviral medications have been approved by the Food and Drug Administration (FDA) for the treatment of influenza, and information about these drugs is summarized in Table 3. They include (1) oseltamivir (Tamiflu), (2) peramivir (Rapivab), (3) baloxavir marboxil (Xofluza), and (4) zanamivir (Relenza). These drugs are categorized according to their mechanism of action. The recommended first-line drugs, the neuraminidase inhibitors (oseltamivir, peramivir, and zanamivir) interfere with the

| Table 3. Food and Drug Administration–Approved Antiviral Influenza Medications |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Drug, Generic (Brand)** | **Route** | **Use** | **Adult Dosage** | **Contraindications** | **Adverse Effects** | **Use in Pregnancy** |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **Neuraminidase inhibitors** | | | | | | |
| Oseltamivir (Tamiflu) | Oral | Treatment and chemoprophylaxis | 75 mg twice daily for 5 d | None | N/V, headache, skin reactions, sporadic transient neuropsychiatric events | May use in pregnancy |
| Peramivir (Rapivab) | Intravenous | Treatment only | 600 mg in a single dose | None | Diarrhea, skin reactions, sporadic transient neuropsychiatric events | Benefits must outweigh risk to take in pregnancy |
| Zanamivir (Relenza) | Inhaled | Treatment and chemoprophylaxis | 10 mg twice daily for 5 d | People with underlying airway disease (eg, asthma, COPD); milk allergy | Risk of bronchospasm in people with underlying airway disease, headache, cough, dizziness, fever, chills, arthralgia, N/V, diarrhea, sinusitis, skin reactions, sporadic transient neuropsychiatric events | May use in pregnancy |
| **CEN inhibitors** | | | | | | |
| Baloxavir marboxil (Xofluza) | Oral | Treatment only | 40-79 kg (88-174 lb): 40 mg in a single dose ≥80 kg (≥175 mg): 80 mg in a single dose | none | Diarrhea, bronchitis, nasopharyngitis, headache, nausea | Avoid in pregnancy |

Abbreviations: CEN, cap-dependent endonuclease; COPD, chronic obstructive pulmonary disease; N/V, nausea and vomiting.

Sources: Gaitonde et al., Uyeki et al., Moscona, Savage.
ability of the influenza virus to spread within the body by inhibiting viral replication. The cap-dependent endonuclease inhibitor (baloxavir marboxil) is the newest antiviral, approved for use by the FDA in 2018, and it works by interfering with the ability of the influenza virus to multiply. Replication of the influenza virus peaks between 24 and 72 hours after onset of illness; therefore, initiation of these antiviral medications should begin as soon as possible. The oldest class of FDA-approved antiviral drugs is the adamantanes (amantadine hydrochloride and rimantadine hydrochloride). Both have traditionally been effective against type A influenza only. However, because of mutations, the influenza virus has become resistant to these 2 drugs, so they are no longer recommended by the CDC for therapy.

Alternative and Complementary Therapies

Because of antigenic shifting when reassortment between different strains of influenza viruses render vaccines and antiviral medications less effective, it is important to discuss with patients alternative and complementary therapies. Patients can be counseled about taking supplemental vitamin D during the influenza season. Because vitamin D is known to have a broad spectrum of activity, including antimicrobial properties, counseling about its potential benefits cannot be excluded. The National Institutes of Health (NIH) recommends vitamin D supplementation of 600 units per day for people aged 1 to 70 years and 800 units per day for those older than 70 years. Vitamin D is needed not only for bone health but also for immune function and its anti-inflammatory properties. People with frequent sunlight exposure often have adequate vitamin D levels to fight off infections, particularly in the summertime. However, during the winter months, many people do not have high enough levels for protection. The NIH has set the upper intake limit of vitamin D supplementation at 4000 units per day. However, no studies have reported adverse effects of supplements with less than 10,000 units per day. Doses greater than 50,000 units per day can raise serum concentrations, leading to hypercalcemia. Symptoms of vitamin D toxicity include nausea, vomiting, dehydration, weight loss, constipation, loss of appetite, lethargy, polyuria, polydipsia, renal dysfunction, and altered sensorium. To prevent infection, Grant et al recommend that people at risk of influenza and/or COVID-19 consider taking 10,000 units vitamin D daily for a few weeks to rapidly raise vitamin D concentrations followed by 5000 units daily. People infected with influenza virus might need even higher doses of vitamin D.

There are no national recommendations for melatonin supplementation against influenza. However, an in vivo study showed that melatonin, a hormone produced and secreted by the pineal gland, has antioxidant and anti-inflammatory properties and plays a role in immunoregulation. Melatonin has been implicated in prevention and/or suppression of influenza infection. It has a high safety profile, and supplemental doses as high as 500 mg daily may lessen infection severity and fatality associated with viral infections, including influenza and COVID-19. This is especially true for people with pre-existing health conditions associated with suppressed melatonin synthesis. Therefore, health care providers may want to counsel individuals about potential beneficial effects of melatonin supplementation. Lastly, individuals can be counseled about increasing consumption of tea catechins (eg, green tea), which have the ability to inhibit viral absorption and enhance immunity.

PREVENTION

Prevention of influenza can occur through vaccination and/or chemoprophylaxis. The choice of which option or use of both is based on the patient’s risk category.

Vaccination

Vaccination is the primary preventive measure against influenza infection and should be offered during all routine health care visits and hospitalizations at any time during influenza season. Vaccine efficacy is about 60% in a good season, but if the vaccine does not match the current circulating strains of the virus, effectiveness can be as low as 10% to 20%. The overall estimated effectiveness of influenza vaccines is 38%.

The overall estimated effectiveness of influenza vaccines is 38%. It is recommended that all people aged 6 months or older receive an annual influenza vaccination unless they have contraindications for the vaccine or any of its components. Ideally, the vaccine should be administered before the end of October because it takes about 2 weeks from vaccination to immunization. However, immunity from vaccination wanes over time, so picking the ideal time to receive the vaccine can be challenging because one cannot predict when influenza outbreaks will peak during the season. Peak time for outbreaks could occur early in the season (eg, October) or late in the season (eg, April or May). Therefore, if an individual receives a vaccine early in the season, they may have less protection if the virus peaks later in the season. The vaccination can be given concurrently with other inactivated vaccines but should be administered in separate anatomic sites.

The health care provider should review common adverse effects from influenza vaccination, which include pain and tenderness at the injection site, headache, fatigue, and muscle or joint pain. Individuals should be taught that adverse reactions to the influenza vaccine are rare but to notify their health care provider if they experience reactions such as urticaria, angioedema, or anaphylaxis. Anaphylaxis is extremely rare.

Vaccine Development

The process of developing a yearly vaccine is lengthy. Every year, the CDC characterizes about 2000 influenza viruses antigenically to monitor for drift or shift and compares them with viruses included in the current influenza vaccine. This information provides an indication of the flu vaccine’s ability to produce an immune response in individuals against current circulating influenza viruses. In addition, antigenic characterization aids CDC experts in their recommendations for which viruses to include in the upcoming seasonal flu vaccine.

The process of choosing which viruses to include involves several steps. First, public health and clinical laboratories partner with the CDC to monitor current circulating strains of influenza. In February each year, the World Health
The live, attenuated influenza vaccine, FluMist (AstraZeneca), which is administered via a nasal spray, is also quadrivalent. This vaccine is egg-based and may be administered to anyone aged 2 to 49 years in the absence of contraindications. Increased risk for Reye’s syndrome has been noted in children who receive the live attenuated influenza vaccine and those who take salicylate-containing drugs (eg, aspirin). Therefore, people aged 2 to 17 years with contraindications should avoid the live attenuated influenza vaccine. The CDC’s Advisory Committee on Immunization Practices (ACIP) recommends that vaccine providers consider observing patients for 15 minutes after administration of the vaccine to decrease the risk of injury if dizziness occurs.

Contraindications to Influenza Vaccine in Adults

Individuals with a history of acquiring Guillain-Barré syndrome within 6 weeks of a previous influenza vaccine should not receive another flu vaccine. Instead, consider using chemoprophylaxis with antiviral medications if they have been exposed to the flu. The influenza vaccine is contraindicated for individuals who have a history of a severe reaction (eg, anaphylaxis) to a previous influenza vaccine, regardless of the component suspected of being responsible for the reaction. Vaccination is not contraindicated for individuals with an egg allergy unless they had a severe reaction to the influenza vaccine previously. Live attenuated vaccines are contraindicated for pregnant women.

Considerations in Prescribing an Influenza Vaccine

The ACIP has no preference for any one influenza vaccine over another for persons who do not have a specific contraindication. Because IIVs and RIVs are suitable for all risk groups, including pregnant and postpartum individuals, the health care provider can choose which vaccine to stock in the primary care setting or prescribe from the pharmacy. It is good practice to have available, in the office, clinic, or pharmacy, a high-dose IIV recommended for individuals aged 65 years or older.

Chemoprophylaxis

Although vaccination is the primary preventive measure for influenza, chemoprophylaxis with oseltamivir or zanamivir is a good alternative in specific circumstances when one has been exposed to the flu, especially for people in high-risk populations. Chemoprophylaxis should be considered if the vaccine and virus are mismatched as a result of antigenic shifting of the virus during the vaccine production or distribution process. In addition, chemoprophylaxis should be considered if there is a supply shortage of influenza vaccines. Vaccine shortages can be the result of egg shortages (eggs are needed for production of most vaccines) or due to a pandemic when the supply of vaccines may be reduced. Table 3 contains information about oseltamivir and zanamivir.
PRECONCEPTION, PREGNANCY, POSTPARTUM, AND NEWBORN

Women who have influenza and are either pregnant or within the 2-week postpartum period are at increased risk of subsequent development of pneumonia. Influenza during pregnancy is associated with increased risk of additional medical visits, hospitalizations, intensive care unit admissions, and adverse perinatal and neonatal outcomes. It is recommended by the CDC’s ACIP, the American College of Nurse-Midwives, and the American College of Obstetricians and Gynecologists that all people aged 6 months and older receive an annual influenza vaccine and most importantly that women who are or will be pregnant (preconception) during flu season receive an IIV, preferably when it is available. Women who are breast feeding may safely receive an IIV as well. Live vaccines should be avoided during pregnancy.

Newborns and infants less than 6 months of age with influenza have higher rates of severe influenza-related complications and higher mortality. Women who receive the influenza vaccination during pregnancy can transfer their antibodies through the placenta to their fetus. The antibodies can protect the child up to 6 months of age, at which time it is recommended that the infant receive their own vaccine. Vaccinating the parents and caregivers may reduce the transmission of influenza to newborns and infants who are too young to receive their own vaccinations. Lastly, it is recommended that women receive the tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap) vaccine during pregnancy for the same reason as getting the influenza vaccination, to provide passive immunity (specifically pertussis). It is especially important to reduce the risk of corespiratory infections with influenza, COVID-19, and/or pertussis during infancy.

IMPLICATIONS FOR CLINICAL PRACTICE

Approximately 45% of individuals receive a seasonal influenza vaccine, which falls short of the 80% goal set by the US Department of Health and Human Services Healthy People 2020 recommendations. Midwives and other health care providers have the opportunity to make a positive impact on morbidity and mortality rates associated with influenza infection. Recommending vaccination and dispelling myths from a multilevel health care team is needed in addition to increasing access to the vaccine. By increasing access there will likely be a spike in the number of individuals receiving the vaccine. Barriers to influenza vaccine uptake include insufficient knowledge about the importance of vaccination, needle phobia, misconception that the vaccine will evoke active influenza infection, and concern about adverse effects. Health care professionals should recognize these barriers and any others in order to dispel misconceptions.

Vaccination rates during pregnancy can be improved by: (1) bundled interventions that target health care providers (eg, standing orders, education, and provider feedback); (2) strategies that increase patient self-initiation and motivation to receive the vaccine; and (3) health care systems (eg, availability of free or low-cost vaccines, adequate supply of vaccines, multimedia educational campaigns). Multilevel interventions orchestrated to include patients, health care clinicians, health care systems, and health care policy should be implemented. Ideally, all individuals will recognize the importance of vaccination, have access to the vaccines, and consent to uptake in order to reduce the unnecessary burden of morbidity and mortality created by seasonal influenza infections.

CONFlict OF INTEREST

The authors have no conflicts of interest to disclose.

REFERENCES

1. Influenza (flu). Centers for Disease Control and Prevention website. Updated July 8, 2020. Accessed August 5, 2020. https://www.cdc.gov/flu/about/burden/index.html
2. Gaitonde DY, Moore FC, Morgan MK. Influenza: diagnosis and treatment. Am Fam Physician. 2019;100(12):751-758.
3. Groshkopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 influenza season. MMWR Recomm Rep. 2019;68(3):1-21.
4. Tokars JJ, Olsen SJ, Reed C. Seasonal incidence of symptomatic influenza in the United States. Clin Infect Dis. 2018;66(10):1511-1518.
5. Biggerstaff M, Kniss K, Jernigan DB, et al. Systematic assessment of multiple routine and near-real time indicators to classify the severity of influenza seasons and pandemics in the United States, 2003-04 through 2015-2016. Am J Epidemiol. 2018;187(5):1040-1050.
6. Quinn SC, Kumar S, Freimuth VS, Musa D, Casteneda-Angarita N, Kidwell K. Racial disparities in exposure, susceptibility, and access to health care in the US H1N1 influenza pandemic. Am J Public Health. 2011;101(2):285-293.
7. Groom AV, Hennessy TW, Singleton RJ, Butler JC, Holve S, Cheek JE. Pneumonia and influenza mortality among American Indian and Alaska native people, 1990-2009. Am J Public Health. 2014;104(S3):S460-S469.
8. Arnold LD, Luong L, Rebmann T, Chang J. Racial disparities in U.S. maternal influenza vaccine uptake: results from analysis of pregnancy risk assessment monitoring system (PRAMS) data, 2012-2015. Vaccine. 2019;37(18):2520-2526.
9. Lu P, O’Halloran A, Williams WW, Lindley MC, Farrall S, Bridges CR. Racial and ethnic disparities in vaccination coverage among adult populations in the U.S. Vaccine. 2015;33:D83-D91.
10. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81(2):266-275.
11. Yue H, Zhang M, Xing L, et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. J Med Virol. 2020;92(11):2870-2873.
12. Maltezou HC, Thedoridou K, Poland G. Influenza immunization and COVID-19. Vaccine. 2020;38(39):6078-6079.
13. Keilman LJ. Seasonal influenza (flu). Nurs Clin North Am. 2019;54(2):227-243.
14. Walton BG. Influenza pandemic and other bugs. Ohio Nurses Rev. 2016;91(6):20.
15. Willyard C. Flu on the farm. Nature. 2019;573(7774):S62-S63.
16. Influenza (flu): Spread of bird flu viruses between animals and people. Centers for Disease Control and Prevention website. Updated February 10, 2015. Accessed August 14, 2020. https://www.cdc.gov/flu/avianflu/virus-transmission.htm
17. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68(6):e47.
18. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute respiratory
infections to healthcare workers: a systematic review. PLoS One. 2012;7(4):e35797.
19.Melikov AK, Al ZT, Markov DG. Intermittent occupancy combined with ventilation: an efficient strategy for the reduction of airborne transmission indoors. Sci Total Environ. 2020;744:140908.
20.Otter JA, Donskey C, Yezli S, Douwtaite S, Goldenberg SD, Weber DJ. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. J Hosp Infect. 2016;92:235–250.
21.Tomlinson S, Behrman S, Cranford J, Louie M, Hashikawa A. Accuracy of smartphone-based pulse oximetry compared with hospital-grade pulse oximetry in healthy children. Telemed J E Health. 2018;24(7):527–535.
22.Peci A, Winter A, King E, Blair J, Gubbay JB. Performance of rapid influenza diagnostic testing in outbreak settings. J Clin Microbiol. 2014;52(12):4309–4317.
23.Saunders-Hastings P, Crispo JAG, Sikora L, Krewski D. Effectiveness of personal protective measures in reducing pandemic influenza transmission: a systematic review and meta-analysis. Epidemics. 2017;20(C):1–20.
24.Influenza (flu): What you need to know. Centers for Disease Control and Prevention website. Updated September 13, 2019. Accessed August 5, 2020. https://www.cdc.gov/flu/keyfacts.htm
25.Ham S. Prevention of exposure to and spread of COVID-19 using air purifiers: challenges and concerns. Epidemiol Health. 2020;42:e2020027.
26.Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353(13):1363–1373.
27.Savage N. A bigger arsenal. Sci Am. 2019;321(5):S34–S55.
28.Vitamin D. Office of Dietary Supplements, National Institutes of Health, website. Updated October 9, 2020. Accessed November 11, 2020. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
29.Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Natrients. 2020;12(4):988.
30.Gailior K, Grebe S, Singh R. Development of vitamin D toxicity from overcorrection of vitamin D deficiency: a review of case reports. Nutrients. 2018;10(8):953.
31.Huang SH, Liao CL, Chen SJ, et al. Melatonin possesses an antinfluenza potential through its immune modulatory effect. J Funct Foods. 2019;58:189–198.
32.Anderson G, Reiter RJ. Melatonin: roles in influenza, Covid-19, and other viral infections. Rev Med Virol. 2020;30(3):e2109.
33.Furushima D, Ide K, Yamada H. Effect of tea catechins on influenza infection and the common cold with a focus on epidemiological/clinical studies. Molecules. 2018;23(7):1795.
34.Einstein M. A shot for all seasons. Nature. 2019;573:s50–s52.
35.McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463–472.
36.Influenza (flu): Antigenic characterization. Centers for Disease Control and Prevention website. Updated October 15, 2019. Accessed October 20, 2020. https://www.cdc.gov/flu/about/professionals/antigenic.htm
37.Influenza (flu): Selecting viruses for the seasonal influenza vaccine. Centers for Disease Control and Prevention website. Updated September 4, 2018. Accessed October 20, 2020. https://www.cdc.gov/flu/prevent/vaccine-selection.htm
38.Groom HC, Henninger ML, Smith N, et al. Influenza vaccination during pregnancy. Am J Prev Med. 2015;50(4):480–488.
39.Wong VWY, Lok KYW. Interventions to increase uptake of seasonal influenza vaccination among pregnancy women: a systematic review. Vaccine. 2016;34(1):20–32.
40.Chu HY, Englund JA. Maternal immunization. Clin Infect Dis. 2014;59(4):560–568.
41.Williams WW, Lu RJ, O’Halloran A, et al. Surveillance of vaccination coverage among adult populations - United States, 2015. MMWR Surveill Summ. 2017;66(11):1–28.
42.Stark LM, Power ML, Torrentine M, et al. Influenza vaccination among pregnant women: patient beliefs and medical provider practices. Infect Dis Obstet Gynecol. 2016;1–8.
43.Falcone AL, Vess J, Johnson E. Evidence-based interventions cause multifold increase of influenza immunization rates in a free clinic. J Am Acad Nurse Prac. 2020;32(12):817–823.
44.Falcone AL. Improving influenza immunization rates in the uninsured. J Am Assoc Nurse Pract. 2019;31(7):391–395.
45.Dykewicz MS, Wallace DV, Baroody F. Treatment of seasonal allergic rhinitis: an evidence based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017;119(6):489–511.
46.Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis. 2005;5(11):718–725.
47.Huang C, Yao X, Zhao Y, et al. Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season. Microbes Infect. 2020;22(6–7):236–244.

Continuing education (CE) is available for this article. To obtain CE online, please visit www.jmwhce.org. A CE form that can be mailed or faxed is available in the print edition of this issue.